Celgene will lose Pomalyst Sales and needs Prurisol.
Celgene Corporation CELG recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Ltd. TEVA submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking an approval to manufacture and market a generic version of Pomalyst (pomalidomide) 1 mg, 2 mg, 3 mg and 4 mg in the U.S.